MIT’s new ‘recursive’ framework lets LLMs process 10 million tokens without context rot

While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...
InfoQ

MIT's Recursive Language Models Improve Performance on Long-Context Tasks

Researchers at MIT's CSAIL published a design for Recursive Language Models (RLM), a technique for improving LLM performance on long-context tasks. RLMs use a programming environment to recursively ...
pharmaphorum

Company Profile: Recursion

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
pharmaphorum

AI biotechs Exscientia and Recursion agree $688m merger

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Unite.AI

When AI Agents Start Building AI: The Recursive Intelligence Explosion Nobody’s Prepared For

For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...
Hosted on MSN

JPMorgan boosts rating on Recursion Pharmaceuticals (RXRX) amid AI-driven drug pipeline

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from a Neutral ...
Barron's

Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...